CA11-SM

About CancerAppy

CancerAppy is a private, preclinical-stage biotech utilizing an AI-driven platform to accelerate oncology drug discovery. Its pipeline includes a first-in-class ADC targeting a novel antigen (ADCGEN-04), a next-generation TEAD inhibitor (CA09-SM), and a PARP1-specific inhibitor (CA11-SM), all aimed at various solid tumors. The company has secured grant funding from Spanish entities and has signed a pre-licensing agreement for its lead ADC program with an undisclosed U.S. company, positioning it for potential partnerships and pipeline advancement.

Therapeutic Areas

Other Epithelial Tumors Drugs